Search

Your search keyword '"Bravi, I."' showing total 4 results
Start Over Author "Bravi, I." Publisher john wiley and sons inc
4 results on '"Bravi, I."'

1. Factors influencing the presence of potentially explosive gases during colonoscopy: Results of the SATISFACTION study

Author

Carnovali, M., Spada, Cristiano, Uebel, P., Bocus, P., Cannizzaro, Rino, Cavallaro, Fabio, Cesana, Bruno Mario, Cesaro, Paola, Costamagna, Guido, Dipaolo, D., Ferrari, A. P., Hinkel, C., Kashin, S., Massella, A., Melnikova, E., Orsatti, A., Ponchon, T., Prada, A., Radaelli, F., Sferrazza, Silvia, Soru, P., Testoni, P. A., Tontini, G. E., Vecchi, M., Fiori, G., Adyshirin, Z. S., Amato, Arianna, Anesi, A., Arpurt, J. P., Attardo, S., Balzarini, M., Bellon, S., Benini, M., Blanc, P., Bonato, G., Bordin, D., Bravi, I., Bulanova, N., Bunkova, E., Cadoni, S., Carparelli, S., Chashkova, E. Y., Ciprandi, Guido, Ciuffini, Cristina, Codazzi, M., Elli, L., Fedorishina, O., Hartmann, D., Jakobs, R., Janke, D., Kamalova, O., Karpova, I., Khitaryan, A., Lombardo, V., Lovera, Mauro, Maiero, S., Manes, G., Martino, G., Merkulova, E., Mura, D., Mutignani, Massimiliano, Occhipinti, P., Pescarolo, M., Petruzziello, Lucio, Pioche, M., Pisani, Anna, Poltorykhina, E., Pretti, C., Puzzono, M., Realdon, S., Reiche, P., Roberto, P., Roman, K., Rondonotti, E., Schettino, M., Segato, S., Shishin, K., Spina, L., Stefania, M., Trovato, C., Valats, J. C., Vena, N., Veselov, V., Viale, E., Vollmar, J., Zavyalov, D., Zimmermann, Thomas Alexander, Spada C. (ORCID:0000-0002-5692-0960), Cannizzaro R., Cavallaro F., Cesana B. M., Cesaro P., Costamagna G. (ORCID:0000-0002-8100-2731), Sferrazza S., Amato A., Ciprandi G., Ciuffini C., Lovera M., Mutignani M. (ORCID:0000-0002-1272-4888), Petruzziello L., Pisani A., Zimmermann T., Carnovali, M., Spada, Cristiano, Uebel, P., Bocus, P., Cannizzaro, Rino, Cavallaro, Fabio, Cesana, Bruno Mario, Cesaro, Paola, Costamagna, Guido, Dipaolo, D., Ferrari, A. P., Hinkel, C., Kashin, S., Massella, A., Melnikova, E., Orsatti, A., Ponchon, T., Prada, A., Radaelli, F., Sferrazza, Silvia, Soru, P., Testoni, P. A., Tontini, G. E., Vecchi, M., Fiori, G., Adyshirin, Z. S., Amato, Arianna, Anesi, A., Arpurt, J. P., Attardo, S., Balzarini, M., Bellon, S., Benini, M., Blanc, P., Bonato, G., Bordin, D., Bravi, I., Bulanova, N., Bunkova, E., Cadoni, S., Carparelli, S., Chashkova, E. Y., Ciprandi, Guido, Ciuffini, Cristina, Codazzi, M., Elli, L., Fedorishina, O., Hartmann, D., Jakobs, R., Janke, D., Kamalova, O., Karpova, I., Khitaryan, A., Lombardo, V., Lovera, Mauro, Maiero, S., Manes, G., Martino, G., Merkulova, E., Mura, D., Mutignani, Massimiliano, Occhipinti, P., Pescarolo, M., Petruzziello, Lucio, Pioche, M., Pisani, Anna, Poltorykhina, E., Pretti, C., Puzzono, M., Realdon, S., Reiche, P., Roberto, P., Roman, K., Rondonotti, E., Schettino, M., Segato, S., Shishin, K., Spina, L., Stefania, M., Trovato, C., Valats, J. C., Vena, N., Veselov, V., Viale, E., Vollmar, J., Zavyalov, D., Zimmermann, Thomas Alexander, Spada C. (ORCID:0000-0002-5692-0960), Cannizzaro R., Cavallaro F., Cesana B. M., Cesaro P., Costamagna G. (ORCID:0000-0002-8100-2731), Sferrazza S., Amato A., Ciprandi G., Ciuffini C., Lovera M., Mutignani M. (ORCID:0000-0002-1272-4888), Petruzziello L., Pisani A., and Zimmermann T.

Abstract

This study tested the hypothesis that bowel preparation with mannitol should not affect the colonic concentration of H2 and CH4. Therefore, the SATISFACTION study, an international, multicenter, randomized, parallel-group phase II–III study investigated this issue. The phase II dose-finding part of the study evaluated H2, CH4, and O2 concentrations in 179 patients randomized to treatment with 50 g, 100 g, or 150 g mannitol. Phase III of the study compared the presence of intestinal gases in 680 patients randomized (1:1) to receive mannitol 100 g in single dose or a standard split-dose 2 L polyethylene glycol (PEG)-Asc preparation (2 L PEG-Asc). Phase II results showed that mannitol did not influence the concentration of intestinal gases. During phase III, no patient in either group had H2 or CH4 concentrations above the critical thresholds. In patients with H2 and/or CH4 levels above detectable concentrations, the mean values were below the risk thresholds by at least one order of magnitude. The results also highlighted the effectiveness of standard washing and insufflation maneuvers in removing residual intestinal gases. In conclusion, bowel cleansing with mannitol was safe as the concentrations of H2 and CH4 were the same as those found in patients prepared with 2 L PEG-Asc. In both groups, the concentrations of gases were influenced more by the degree of cleansing achieved and the insufflation and washing maneuvers performed than by the preparation used for bowel cleansing. The trial protocol was registered with ClinicalTrials.gov (https://clinicaltrials.gov/ct2/show/NCT04759885) and with EudraCT (eudract_number: 2019-002856-18).

Published
2023

2. Factors influencing the presence of potentially explosive gases during colonoscopy: Results of the SATISFACTION study

Author

Carnovali, M., Spada, Cristiano, Uebel, P., Bocus, P., Cannizzaro, Rino, Cavallaro, Fabio, Cesana, Bruno Mario, Cesaro, Paola, Costamagna, Guido, Dipaolo, D., Ferrari, A. P., Hinkel, C., Kashin, S., Massella, A., Melnikova, E., Orsatti, A., Ponchon, T., Prada, A., Radaelli, F., Sferrazza, Silvia, Soru, P., Testoni, P. A., Tontini, G. E., Vecchi, M., Fiori, G., Adyshirin, Z. S., Amato, Arianna, Anesi, A., Arpurt, J. P., Attardo, S., Balzarini, M., Bellon, S., Benini, M., Blanc, P., Bonato, G., Bordin, D., Bravi, I., Bulanova, N., Bunkova, E., Cadoni, S., Carparelli, S., Chashkova, E. Y., Ciprandi, Guido, Ciuffini, Cristina, Codazzi, M., Elli, L., Fedorishina, O., Hartmann, D., Jakobs, R., Janke, D., Kamalova, O., Karpova, I., Khitaryan, A., Lombardo, V., Lovera, Mauro, Maiero, S., Manes, G., Martino, G., Merkulova, E., Mura, D., Mutignani, Massimiliano, Occhipinti, P., Pescarolo, M., Petruzziello, Lucio, Pioche, M., Pisani, Anna, Poltorykhina, E., Pretti, C., Puzzono, M., Realdon, S., Reiche, P., Roberto, P., Roman, K., Rondonotti, E., Schettino, M., Segato, S., Shishin, K., Spina, L., Stefania, M., Trovato, C., Valats, J. C., Vena, N., Veselov, V., Viale, E., Vollmar, J., Zavyalov, D., Zimmermann, Thomas Alexander, Spada C. (ORCID:0000-0002-5692-0960), Cannizzaro R., Cavallaro F., Cesana B. M., Cesaro P., Costamagna G. (ORCID:0000-0002-8100-2731), Sferrazza S., Amato A., Ciprandi G., Ciuffini C., Lovera M., Mutignani M. (ORCID:0000-0002-1272-4888), Petruzziello L., Pisani A., Zimmermann T., Carnovali, M., Spada, Cristiano, Uebel, P., Bocus, P., Cannizzaro, Rino, Cavallaro, Fabio, Cesana, Bruno Mario, Cesaro, Paola, Costamagna, Guido, Dipaolo, D., Ferrari, A. P., Hinkel, C., Kashin, S., Massella, A., Melnikova, E., Orsatti, A., Ponchon, T., Prada, A., Radaelli, F., Sferrazza, Silvia, Soru, P., Testoni, P. A., Tontini, G. E., Vecchi, M., Fiori, G., Adyshirin, Z. S., Amato, Arianna, Anesi, A., Arpurt, J. P., Attardo, S., Balzarini, M., Bellon, S., Benini, M., Blanc, P., Bonato, G., Bordin, D., Bravi, I., Bulanova, N., Bunkova, E., Cadoni, S., Carparelli, S., Chashkova, E. Y., Ciprandi, Guido, Ciuffini, Cristina, Codazzi, M., Elli, L., Fedorishina, O., Hartmann, D., Jakobs, R., Janke, D., Kamalova, O., Karpova, I., Khitaryan, A., Lombardo, V., Lovera, Mauro, Maiero, S., Manes, G., Martino, G., Merkulova, E., Mura, D., Mutignani, Massimiliano, Occhipinti, P., Pescarolo, M., Petruzziello, Lucio, Pioche, M., Pisani, Anna, Poltorykhina, E., Pretti, C., Puzzono, M., Realdon, S., Reiche, P., Roberto, P., Roman, K., Rondonotti, E., Schettino, M., Segato, S., Shishin, K., Spina, L., Stefania, M., Trovato, C., Valats, J. C., Vena, N., Veselov, V., Viale, E., Vollmar, J., Zavyalov, D., Zimmermann, Thomas Alexander, Spada C. (ORCID:0000-0002-5692-0960), Cannizzaro R., Cavallaro F., Cesana B. M., Cesaro P., Costamagna G. (ORCID:0000-0002-8100-2731), Sferrazza S., Amato A., Ciprandi G., Ciuffini C., Lovera M., Mutignani M. (ORCID:0000-0002-1272-4888), Petruzziello L., Pisani A., and Zimmermann T.

Abstract

This study tested the hypothesis that bowel preparation with mannitol should not affect the colonic concentration of H2 and CH4. Therefore, the SATISFACTION study, an international, multicenter, randomized, parallel-group phase II–III study investigated this issue. The phase II dose-finding part of the study evaluated H2, CH4, and O2 concentrations in 179 patients randomized to treatment with 50 g, 100 g, or 150 g mannitol. Phase III of the study compared the presence of intestinal gases in 680 patients randomized (1:1) to receive mannitol 100 g in single dose or a standard split-dose 2 L polyethylene glycol (PEG)-Asc preparation (2 L PEG-Asc). Phase II results showed that mannitol did not influence the concentration of intestinal gases. During phase III, no patient in either group had H2 or CH4 concentrations above the critical thresholds. In patients with H2 and/or CH4 levels above detectable concentrations, the mean values were below the risk thresholds by at least one order of magnitude. The results also highlighted the effectiveness of standard washing and insufflation maneuvers in removing residual intestinal gases. In conclusion, bowel cleansing with mannitol was safe as the concentrations of H2 and CH4 were the same as those found in patients prepared with 2 L PEG-Asc. In both groups, the concentrations of gases were influenced more by the degree of cleansing achieved and the insufflation and washing maneuvers performed than by the preparation used for bowel cleansing. The trial protocol was registered with ClinicalTrials.gov (https://clinicaltrials.gov/ct2/show/NCT04759885) and with EudraCT (eudract_number: 2019-002856-18).

Published
2023

3. Pharmacokinetics of oral mannitol for bowel preparation for colonoscopy

Author

Fiori, G., Spada, Cristiano, Soru, P., Tontini, G. E., Bravi, I., Cesana, Bruno Mario, Cesaro, Paola, Manes, G., Orsatti, A., Prada, A., Quadarella, Alessandro, Schettino, M., Spina, L., Trovato, C., Carnovali, M., Vecchi, M., Cavallaro, Fabio, Codazzi, M., De Nucci, G., De Roberto, G., Devani, M., Di Paolo, D., Elli, L., Hinkel, C., Jakobs, R., Janke, D., Lombardo, V., Lovera, Mauro, Radaelli, F., Ravizza, D., Uebel, P., Valats, J. C., Vollmar, J., Zimmermann, Thomas Alexander, Ciprandi, Guido, Spada C. (ORCID:0000-0002-5692-0960), Cesana B. M., Cesaro P., Quadarella A., Cavallaro F., Lovera M., Zimmermann T., Ciprandi G., Fiori, G., Spada, Cristiano, Soru, P., Tontini, G. E., Bravi, I., Cesana, Bruno Mario, Cesaro, Paola, Manes, G., Orsatti, A., Prada, A., Quadarella, Alessandro, Schettino, M., Spina, L., Trovato, C., Carnovali, M., Vecchi, M., Cavallaro, Fabio, Codazzi, M., De Nucci, G., De Roberto, G., Devani, M., Di Paolo, D., Elli, L., Hinkel, C., Jakobs, R., Janke, D., Lombardo, V., Lovera, Mauro, Radaelli, F., Ravizza, D., Uebel, P., Valats, J. C., Vollmar, J., Zimmermann, Thomas Alexander, Ciprandi, Guido, Spada C. (ORCID:0000-0002-5692-0960), Cesana B. M., Cesaro P., Quadarella A., Cavallaro F., Lovera M., Zimmermann T., and Ciprandi G.

Abstract

This study aimed to define the pharmacokinetics (PKs) of oral mannitol used as an osmotic laxative for bowel preparation for colonoscopy. The PKs of oral mannitol was evaluated in a substudy as part of a phase II dose-finding, international, multicenter, randomized, parallel-group, endoscopist-blinded study. Patients were randomly assigned to take 50, 100, or 150 g mannitol. Venous blood samples were drawn at baseline (T0), 1 h (T1), 2 h (T2), 4 h (T4), and 8 h (T8) after completion of mannitol self-administration. The mean mannitol plasma concentrations (mg/ml) were dose-dependent with a consistent difference among doses. The mean maximum concentration (Cmax) ± SD was 0.63 ± 0.15, 1.02 ± 0.28, and 1.36 ± 0.39 mg/ml, in the three dosage groups, respectively. The mean area under the curve from zero to infinity (AUC0−∞) was 2.667 ± 0.668, 4.992 ± 1.706, and 7.403 ± 3.472 mg/ml*h in the 50, 100, and 150 g mannitol dose groups, respectively. Bioavailability was similar in the three dose groups and was just over 20% (0.243 ± 0.073, 0.209 ± 0.081, and 0.228 ± 0.093 in the 50, 100, and 150 g mannitol dose groups, respectively). The present study showed that the bioavailability of oral mannitol is just over 20% and is similar for the three tested doses (50, 100, and 150 g). The linear increase in Cmax, AUC0−t8, and AUC0−∞ must be considered when choosing the oral mannitol dose for bowel preparation to avoid its systemic osmotic effects.

Published
2022

4. Pharmacokinetics of oral mannitol for bowel preparation for colonoscopy

Author

Fiori, G., Spada, Cristiano, Soru, P., Tontini, G. E., Bravi, I., Cesana, Bruno Mario, Cesaro, Paola, Manes, G., Orsatti, A., Prada, A., Quadarella, Alessandro, Schettino, M., Spina, L., Trovato, C., Carnovali, M., Vecchi, M., Cavallaro, Fabio, Codazzi, M., De Nucci, G., De Roberto, G., Devani, M., Di Paolo, D., Elli, L., Hinkel, C., Jakobs, R., Janke, D., Lombardo, V., Lovera, Mauro, Radaelli, F., Ravizza, D., Uebel, P., Valats, J. C., Vollmar, J., Zimmermann, Thomas Alexander, Ciprandi, Guido, Spada C. (ORCID:0000-0002-5692-0960), Cesana B. M., Cesaro P., Quadarella A., Cavallaro F., Lovera M., Zimmermann T., Ciprandi G., Fiori, G., Spada, Cristiano, Soru, P., Tontini, G. E., Bravi, I., Cesana, Bruno Mario, Cesaro, Paola, Manes, G., Orsatti, A., Prada, A., Quadarella, Alessandro, Schettino, M., Spina, L., Trovato, C., Carnovali, M., Vecchi, M., Cavallaro, Fabio, Codazzi, M., De Nucci, G., De Roberto, G., Devani, M., Di Paolo, D., Elli, L., Hinkel, C., Jakobs, R., Janke, D., Lombardo, V., Lovera, Mauro, Radaelli, F., Ravizza, D., Uebel, P., Valats, J. C., Vollmar, J., Zimmermann, Thomas Alexander, Ciprandi, Guido, Spada C. (ORCID:0000-0002-5692-0960), Cesana B. M., Cesaro P., Quadarella A., Cavallaro F., Lovera M., Zimmermann T., and Ciprandi G.

Abstract

This study aimed to define the pharmacokinetics (PKs) of oral mannitol used as an osmotic laxative for bowel preparation for colonoscopy. The PKs of oral mannitol was evaluated in a substudy as part of a phase II dose-finding, international, multicenter, randomized, parallel-group, endoscopist-blinded study. Patients were randomly assigned to take 50, 100, or 150 g mannitol. Venous blood samples were drawn at baseline (T0), 1 h (T1), 2 h (T2), 4 h (T4), and 8 h (T8) after completion of mannitol self-administration. The mean mannitol plasma concentrations (mg/ml) were dose-dependent with a consistent difference among doses. The mean maximum concentration (Cmax) ± SD was 0.63 ± 0.15, 1.02 ± 0.28, and 1.36 ± 0.39 mg/ml, in the three dosage groups, respectively. The mean area under the curve from zero to infinity (AUC0−∞) was 2.667 ± 0.668, 4.992 ± 1.706, and 7.403 ± 3.472 mg/ml*h in the 50, 100, and 150 g mannitol dose groups, respectively. Bioavailability was similar in the three dose groups and was just over 20% (0.243 ± 0.073, 0.209 ± 0.081, and 0.228 ± 0.093 in the 50, 100, and 150 g mannitol dose groups, respectively). The present study showed that the bioavailability of oral mannitol is just over 20% and is similar for the three tested doses (50, 100, and 150 g). The linear increase in Cmax, AUC0−t8, and AUC0−∞ must be considered when choosing the oral mannitol dose for bowel preparation to avoid its systemic osmotic effects.

Published
2022

Catalog

Books, media, physical & digital resources
See catalog results